Recently, Boston Pharmaceuticals reached an agreement with Novartis and GlaxoSmithKline (GSK) to harvest a variety of potential drug candidates. The three antibiotics obtained from Novartis are expected to treat drug-resistant bacterial infections. The five drugs under study from GSK can be used to treat diseases such as acne, psoriasis and diarrhea-type irritable bowel syndrome. Under the agreement with Novartis, Boston Pharmaceuticals will receive a global R&D license for three new anti-infective drug candidates, two complementary drug candidates for the carbapenem-resistant Enterobacteriaceae (CRE), and one for A drug candidate for monosporia is expected to be a new drug for the treatment of drug-resistant Gram-negative bacteria. Boston Pharmaceuticals will make advance payments to Novartis and milestone payments and sales breaks after successful drug promotion. The three candidate drugs involved in this agreement are specifically: LYS228, a monoamicin that has the potential to become a "best-in-class", has entered Phase 2 clinical development and has been shown to be resistant to serine beta-lactamase (SBL) and/or metal beta- Resistance to carbapenem-resistant Enterobacteriaceae (CRE) caused by lactamase (MBL); IID572, a novel beta-lactamase inhibitor, can be used in combination with LYS228 or other beta-lactam antibiotics to combat difficult-to-treat infections caused by the wider CRE; MAK181, an oral "first-in-class" LpxC inhibitor for Pseudomonas infection. “People clearly need new antibiotics that fight resistant bacteria. We are pleased to partner with Boston Pharmaceuticals to put the right expertise and resources into the further development and promotion of these projects,†said Jay, President of Novartis Biomedical Research Institute. Dr. Bradner said: "Drug discovery and development is a team activity. This agreement is part of our strategy to work with like-minded innovators to further develop new and innovative drugs that address global health challenges." "The acquisition of these three new anti-infective drug candidates further demonstrates our commitment to address unmet medical needs to benefit patients," said Dr. Robert Armstrong, CEO of Boston Pharmaceuticals: "Nova has done a lot of work to drive new The program addresses infections caused by drug-resistant Gram-negative pathogens and develops innovative drug candidates that are expected to become 'best-in-class' and 'first-in-class'. We look forward to advancing these drug candidates while Continue to build high quality research." Under the agreement with GSK, Boston Pharmaceuticals will receive a portfolio of five early development projects. These products include two drug candidates that can enter Phase 2 R&D, a drug candidate that can enter Phase 1 R&D, and two drug candidates for unpublished preclinical programs. Boston Pharmaceuticals will assume full responsibility for advancing these clinical phase projects. The three publicly available drug candidates involved in this agreement are specifically: GSK3352589, a novel small molecule inhibitor for transfection rearrangement (RET) tyrosine kinase, for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), has completed Phase 1 studies; GSK3008356, a potent selective small molecule inhibitor against diglyceride acyltransferase (DGAT) 1, which can be used to treat acne, has completed Phase 1 studies; GSK3183475, a novel small molecule inhibitor for BET BD2 (Bromodomain and Extra-Terminal, Second Bromodomain), can be used as a topical preparation for the treatment of vitiligo and/or psoriasis and is currently available in Phase 1 studies. “Getting a R&D license for these products is an important validation of our development team's capabilities and a recognition of our strategy to create a diverse range of clinical drug candidates across a variety of indications,†said Dr. Robert Armstrong, CEO of Boston Pharmaceuticals. We have made substantial progress in implementing our business model and are pleased to bring these molecules to the clinic to assess their potential to improve patient life." Reference materials: [1] Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK. Retrieved October 4, 2018, from https:// [2] Boston Pharmaceuticals. Retrieved October 4, 2018, from https:// Powder Fire Extinguisher,Powder Type Fire Extinguisher,Dry Powder Fire Extinguisher,Dry Powder Extinguisher JIANGSU NEW FIRE FIGHTING TECHNOLOGY CO.,LTD , https://www.ffo2cylinder.com